CAPR
Capricor Therapeutics Inc
NASDAQ · Biotechnology
$24.72
+1.69 (+7.34%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 34.40M | 187.20M | 168.99M | 200.90M |
| Net Income | -62,506,501 | 36.18M | 32.84M | 38.17M |
| EPS | — | — | — | — |
| Profit Margin | -181.7% | 19.3% | 19.4% | 19.0% |
| Rev Growth | +352.7% | +21.4% | +1.7% | +17.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 15.25M | 560.43M | 596.69M | 549.88M |
| Total Equity | 657.15M | 433.52M | 435.03M | 413.42M |
| D/E Ratio | 0.02 | 1.29 | 1.37 | 1.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -63,708,759 | 59.64M | 51.36M | 64.78M |
| Free Cash Flow | — | 19.67M | 27.43M | 19.13M |